[go: up one dir, main page]

FR16C0016I1 - - Google Patents

Info

Publication number
FR16C0016I1
FR16C0016I1 FR16C0016C FR16C0016I1 FR 16C0016 I1 FR16C0016 I1 FR 16C0016I1 FR 16C0016 C FR16C0016 C FR 16C0016C FR 16C0016 I1 FR16C0016 I1 FR 16C0016I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR16C0016I1 publication Critical patent/FR16C0016I1/fr
Application granted granted Critical
Publication of FR16C0016I2 publication Critical patent/FR16C0016I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
FR16C0016C 2000-03-10 2016-04-29 MODIFIED FACTOR VIII Active FR16C0016I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (2)

Publication Number Publication Date
FR16C0016I1 true FR16C0016I1 (en) 2016-04-29
FR16C0016I2 FR16C0016I2 (en) 2018-11-02

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0016C Active FR16C0016I2 (en) 2000-03-10 2016-04-29 MODIFIED FACTOR VIII

Country Status (35)

Country Link
US (3) US6458563B1 (en)
EP (1) EP1280540B1 (en)
JP (1) JP4044337B2 (en)
KR (1) KR100485525B1 (en)
CN (1) CN1191360C (en)
AT (1) ATE391512T1 (en)
AU (2) AU2001238416B2 (en)
BE (1) BE2016C024I2 (en)
BR (2) BR122013026957A8 (en)
CA (1) CA2400295C (en)
CY (2) CY1108179T1 (en)
CZ (1) CZ298250B6 (en)
DE (1) DE60133541T2 (en)
DK (1) DK1280540T3 (en)
EE (1) EE05075B1 (en)
ES (1) ES2304379T3 (en)
FR (1) FR16C0016I2 (en)
HU (2) HU227804B1 (en)
IL (2) IL151371A0 (en)
LT (1) LTC1280540I2 (en)
LU (1) LU93049I2 (en)
ME (1) ME00601B (en)
MX (1) MXPA02008798A (en)
NL (1) NL300808I2 (en)
NO (2) NO331935B1 (en)
NZ (1) NZ520799A (en)
PL (1) PL202936B1 (en)
PT (1) PT1280540E (en)
RS (1) RS50364B (en)
RU (1) RU2285724C2 (en)
SI (1) SI1280540T1 (en)
SK (1) SK286205B6 (en)
UA (1) UA75064C2 (en)
WO (1) WO2001068109A1 (en)
ZA (1) ZA200206810B (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
AU2002248329B2 (en) * 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
EP1572889B1 (en) * 2001-10-05 2008-12-17 Expression Therapeutics, LLC Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
US20040249134A1 (en) * 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7709224B2 (en) * 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
DE602004007924T2 (en) * 2003-06-26 2008-04-10 Merck Patent Gmbh THROMBOPOIETINE PROTEINS WITH IMPROVED PROPERTIES
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
WO2005055930A2 (en) * 2003-12-03 2005-06-23 University Of Rochester Recombinant factor viii having increased specific activity
WO2005107776A1 (en) * 2004-05-03 2005-11-17 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
LT1824988T (en) * 2004-11-12 2017-10-25 Bayer Healthcare Llc MODIFIED FVIII MODIFICATION RELATED TO A RELATED Link
US20100256062A1 (en) 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1968999A2 (en) 2005-12-07 2008-09-17 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
PL2007885T3 (en) * 2006-04-11 2010-12-31 Csl Behring Gmbh Method of increasing the in vivo recovery of therapeutic polypeptides
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
KR101542752B1 (en) * 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (en) * 2007-02-23 2012-11-23 Biomethodes NEW VIII FACTORS FOR THE TREATMENT OF TYPE A HEMOPHILS
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
CN104152489A (en) * 2007-11-01 2014-11-19 罗切斯特大学 Recombinant factor VIII having increased stability
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
PL2393828T3 (en) 2009-02-03 2017-06-30 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
PL2440239T3 (en) 2009-06-09 2018-01-31 Prolong Pharmaceuticals Llc HEMOGLOBIN COMPOSITIONS
EP2742949A1 (en) * 2009-11-13 2014-06-18 Puget Sound Blood Center Factor VIII B cell epitope variants having reduced immunogenicity
AU2010325787B2 (en) 2009-12-06 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP2635297B1 (en) 2010-11-05 2019-02-27 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity
EP2661488A1 (en) * 2011-01-05 2013-11-13 Expression Therapeutics, LLC Method and system for suspension cell culture
PT2717898T (en) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Pro-coagulant compounds and methods of use thereof
KR102110736B1 (en) 2011-07-08 2020-05-14 바이오버라티브 테라퓨틱스 인크. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CN102277379B (en) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 Expression vector for expressing coagulation factor VIII and application thereof
HRP20191920T1 (en) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
HUE041595T2 (en) 2012-01-12 2019-05-28 Bioverativ Therapeutics Inc Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
CN119192402A (en) 2012-02-15 2024-12-27 比奥贝拉蒂治疗公司 Factor VIII compositions and methods of making and using the same
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc CHIMERIC COAGULATION FACTORS
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
PL2882450T3 (en) 2012-07-11 2020-06-29 Bioverativ Therapeutics Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc Methods of using fviii polypeptide
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
PL2956477T5 (en) 2013-02-15 2024-05-27 Bioverativ Therapeutics Inc. Optimized factor viii gene
EA201890671A1 (en) 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. DRUGS OF POLYPEPTIDE FACTOR VIII
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AU2014302100B2 (en) 2013-06-28 2020-02-13 Bioverativ Therapeutics Inc. Thrombin cleavable linker with XTEN and its uses thereof
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
BR112016009064A2 (en) 2013-10-22 2017-09-19 Inst Nat Sante Rech Med CUTANEOUS PATTER DEVICE; DRUG RELEASE SYSTEM; KIT; AND METHOD OF TREATMENT OF HEMOPHILIA IN AN INDIVIDUAL IN NEED OF THE SAME
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (en) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Population pharmacokinetics tools and their uses
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
FI4176894T3 (en) 2014-01-10 2024-05-29 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015127129A1 (en) * 2014-02-19 2015-08-27 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
PE20231949A1 (en) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTS OF FACTOR VIII REDUCED WITH CpG, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASY DISORDERS
EA202190827A1 (en) 2015-11-13 2021-11-30 Баксалта Инкорпорейтед VIRAL VECTORS CODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
MX2018005969A (en) 2015-11-13 2018-11-29 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a.
PT3411478T (en) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENES
KR102175878B1 (en) 2016-06-24 2020-11-06 재단법인 목암생명과학연구소 Chimeric proteins containing FVIII and VWF factors and uses thereof
BR112019011198A2 (en) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc methods of inducing immune tolerance to coagulation factors
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
WO2018208973A1 (en) 2017-05-09 2018-11-15 Emory University Clotting factor variants and their use
WO2019032898A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
JP2021512126A (en) 2018-02-01 2021-05-13 バイオベラティブ セラピューティクス インコーポレイテッド Use of a lentiviral vector expressing factor VIII
UY38160A (en) 2018-04-04 2019-11-29 Sigilon Therapeutics Inc IMPLANTABLE PARTICLES AND RELATED METHODS
TW202015723A (en) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 Methods of treating hemophilia a
KR20210034013A (en) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 Genetic treatment of hemophilia using viral vectors encoding recombinant FVIII variants with increased expression
SG11202101157VA (en) 2018-08-09 2021-03-30 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
TWI851647B (en) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
TW202115127A (en) 2019-06-19 2021-04-16 美商百歐維拉提夫治療公司 Methods and compositions for treating hemophilia and low bone mineral density
EP3986481A2 (en) 2019-06-20 2022-04-27 Takeda Pharmaceutical Company Limited Method of treatment with viral-based gene therapy
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
EP4073106A2 (en) 2019-12-12 2022-10-19 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
TW202246505A (en) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 Codon-optimized nucleic acid that encodes coagulation factor ix protein, and use thereof
CN117098996A (en) * 2021-03-31 2023-11-21 美国血液技术公司 Hemostatic measuring device quality control preparations
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
AR126846A1 (en) 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENES
EP4408874A1 (en) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
JPH0788399B2 (en) * 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド Novel procoagulant protein
JPH0387173A (en) 1987-09-10 1991-04-11 Teijin Ltd Preparation of human active natural type factor viii c and transformant using the same
DK162233C (en) 1989-11-09 1992-03-16 Novo Nordisk As PROCEDURE FOR INSULATING FACTOR VIII FROM BLOOD PLASMA AND PHARMACEUTICAL PREPARATION CONTAINING THE ASSOCIATED PHATAR VIII
AU656720B2 (en) * 1989-12-01 1995-02-16 Gene Pharming Europe Bv Production of recombinant polypeptides by bovine species and transgenic methods
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
MXPA03002256A (en) * 2000-09-19 2003-09-10 Univ Emory Modified factor viii.
US20040249134A1 (en) * 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
KR100485525B1 (en) 2005-04-28
BR122013026957A8 (en) 2017-02-21
HUP0300586A3 (en) 2006-11-28
WO2001068109A1 (en) 2001-09-20
LTC1280540I2 (en) 2020-05-25
HUS1600020I1 (en) 2016-06-28
CY2016011I1 (en) 2016-10-05
MXPA02008798A (en) 2003-04-25
AU2001238416B2 (en) 2004-09-02
YU68002A (en) 2005-11-28
EP1280540A4 (en) 2004-11-03
JP4044337B2 (en) 2008-02-06
CZ298250B6 (en) 2007-08-01
MEP8209A (en) 2011-12-20
US7122634B2 (en) 2006-10-17
EP1280540A1 (en) 2003-02-05
NO331935B1 (en) 2012-05-07
BR0109131A (en) 2004-12-07
IL151371A (en) 2010-12-30
DK1280540T3 (en) 2008-07-14
JP2003526358A (en) 2003-09-09
CN1191360C (en) 2005-03-02
IL151371A0 (en) 2003-04-10
BR122013026957A2 (en) 2004-12-07
CY1108179T1 (en) 2014-02-12
SI1280540T1 (en) 2008-08-31
EE05075B1 (en) 2008-10-15
HU227804B1 (en) 2012-03-28
DE60133541T2 (en) 2009-05-07
NZ520799A (en) 2004-06-25
BE2016C024I2 (en) 2020-01-30
DE60133541D1 (en) 2008-05-21
US20030068785A1 (en) 2003-04-10
NO20024296L (en) 2002-11-08
PL202936B1 (en) 2009-08-31
NO20024296D0 (en) 2002-09-09
RU2285724C2 (en) 2006-10-20
SK14392002A3 (en) 2003-06-03
HK1051004A1 (en) 2003-07-18
PL359672A1 (en) 2004-09-06
NL300808I1 (en) 2016-05-18
KR20020081426A (en) 2002-10-26
PT1280540E (en) 2008-06-09
LU93049I2 (en) 2016-06-27
ES2304379T3 (en) 2008-10-16
US6458563B1 (en) 2002-10-01
ATE391512T1 (en) 2008-04-15
CZ20023346A3 (en) 2003-01-15
BRPI0109131B8 (en) 2021-07-06
FR16C0016I2 (en) 2018-11-02
UA75064C2 (en) 2006-03-15
BRPI0109131B1 (en) 2020-08-25
CA2400295A1 (en) 2001-09-20
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
HUP0300586A2 (en) 2003-06-28
US7012132B2 (en) 2006-03-14
CY2016011I2 (en) 2016-10-05
NL300808I2 (en) 2020-12-21
RU2002124123A (en) 2004-03-27
AU3841601A (en) 2001-09-24
SK286205B6 (en) 2008-05-06
CA2400295C (en) 2012-01-10
EP1280540B1 (en) 2008-04-09
CN1416348A (en) 2003-05-07
ME00601B (en) 2011-12-20
EE200200510A (en) 2004-02-16
NO2016007I1 (en) 2016-05-10
NO2016007I2 (en) 2016-05-10
RS50364B (en) 2009-11-10

Similar Documents

Publication Publication Date Title
FR16C0016I1 (en)
BE2010C019I2 (en)
BE2011C032I2 (en)
BRPI0113085B8 (en)
JP2002537095A5 (en)
JP2003518266A5 (en)
BE2010C040I2 (en)
JP2003519584A5 (en)
JP2003508812A5 (en)
JP2002063763A5 (en)
JP2002055124A5 (en)
JP2002182086A5 (en)
JP2003518646A5 (en)
CN3142145S (en)
AU2000256023A8 (en)
AU2000273097A8 (en)
AU2000256695A8 (en)
CN3141410S (en)
CN3141400S (en)
CN3141399S (en)
CN3141005S (en)
CN3140481S (en)
CN3139848S (en)
CN3138983S (en)
CN3141860S (en)